Back to Browse Journals » Clinical Ophthalmology » Volume 7

Comparative effectiveness of aflibercept for the treatment of patients with neovascular age-related macular degeneration

Authors Thomas M, Mousa SS, Mousa SA

Received 15 November 2012

Accepted for publication 5 February 2013

Published 8 March 2013 Volume 2013:7 Pages 495—501


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Michael Thomas,1 Shaymaa S Mousa,2 Shaker A Mousa1

1Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Albany, NY, USA; 2The Johns Hopkins University, Baltimore, MD, USA

Abstract: Wet age-related macular degeneration (AMD) is the most common reason for vision loss in the United States. Many treatments, such as laser therapy and photodynamic therapies, have been used but their efficacy is limited. Emerging anti-vascular endothelial growth factor (VEGF) therapies are now considered the standard of care. Anti-VEGF agents inhibit angiogenesis in the eye by suppressing abnormal blood vessel growth, leading to vision improvement. Ranibizumab and bevacizumab are two examples of anti-VEGF drugs that have been approved; both showed promise based on the visual acuity scale. Aflibercept, another new therapy known to trap VEGF and inhibit multiple growth factors, is promising not only because it can be taken bimonthly based on year 1 of the VIEW trials, but it can also be extended, as demonstrated in year 2 of the VIEW trials. Based on a cost–effect analysis, aflibercept is comparable to other leading therapies. This is a review of relevant clinical trials that have proven the non-inferiority and safety of aflibercept compared to the standard of care and its unique role in the current management of wet AMD.

Keywords: aflibercept, VEGF, anti-VEGF, pegatanib, bevacizumab, ranibizumab, VIEW trials

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] View Full Text [HTML] 


Other articles by this author:

Current primary open-angle glaucoma treatments and future directions

Beidoe G, Mousa SA

Clinical Ophthalmology 2012, 6:1699-1707

Published Date: 23 October 2012

Biosensors: the new wave in cancer diagnosis

Brian Bohunicky, Shaker A Mousa

Nanotechnology, Science and Applications 2011, 4:1-10

Published Date: 30 December 2010

Pharmacogenetics in breast cancer: steps toward personalized medicine in breast cancer management

Sarah Rofaiel, Esther N Muo, Shaker A Mousa

Pharmacogenomics and Personalized Medicine 2010, 3:129-143

Published Date: 17 September 2010

Prevention strategies for antimicrobial resistance: a systematic review of the literature

Whitney P Caron, Shaker A Mousa

Infection and Drug Resistance 2010, 3:25-33

Published Date: 21 May 2010

Pharmacogenomics in type II diabetes mellitus management: Steps toward personalized medicine

Peter Avery, Shaymaa S Mousa, Shaker A Mousa

Pharmacogenomics and Personalized Medicine 2009, 2:79-91

Published Date: 13 September 2009

Pharmacogenomics in osteoporosis: Steps toward personalized medicine

Robert Greene, Shaymaa S Mousa, Mohamed Ardawi, et al

Pharmacogenomics and Personalized Medicine 2009, 2:69-78

Published Date: 10 September 2009

The implications of pharmacogenomics in the treatment of HIV-1-infected patients of African descent

Hector Clarke, Shaker A Mousa

Pharmacogenomics and Personalized Medicine 2009, 2:93-99

Published Date: 10 September 2009

Pharmacogenomics in cardiovascular disorders: Steps in approaching personalized medicine in cardiovascular medicine

Christopher Barone, Shaymaa S Mousa, Shaker A Mousa

Pharmacogenomics and Personalized Medicine 2009, 2:59-67

Published Date: 8 September 2009

Readers of this article also read:

Green synthesis of water-soluble nontoxic polymeric nanocomposites containing silver nanoparticles

Prozorova GF, Pozdnyakov AS, Kuznetsova NP, Korzhova SA, Emel’yanov AI, Ermakova TG, Fadeeva TV, Sosedova LM

International Journal of Nanomedicine 2014, 9:1883-1889

Published Date: 16 April 2014

Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects [Corrigendum]

Cui Y, Song Y, Wang J, Yu Z, Schuster A, Barrett YC, Frost C

Clinical Pharmacology: Advances and Applications 2014, 6:61-62

Published Date: 27 March 2014

Pharmacokinetics and pharmacodynamics of acetylsalicylic acid after intravenous and oral administration to healthy volunteers

Nagelschmitz J, Blunck M, Kraetzschmar J, Ludwig M, Wensing G, Hohlfeld T

Clinical Pharmacology: Advances and Applications 2014, 6:51-59

Published Date: 19 March 2014

Methacrylic-based nanogels for the pH-sensitive delivery of 5-Fluorouracil in the colon

Ashwanikumar N, Kumar NA, Nair SA, Kumar GS

International Journal of Nanomedicine 2012, 7:5769-5779

Published Date: 15 November 2012

A novel preparation method for silicone oil nanoemulsions and its application for coating hair with silicone

Hu Z, Liao M, Chen Y, Cai Y, Meng L, Liu Y, Lv N, Liu Z, Yuan W

International Journal of Nanomedicine 2012, 7:5719-5724

Published Date: 12 November 2012

Cross-linked acrylic hydrogel for the controlled delivery of hydrophobic drugs in cancer therapy

Deepa G, Thulasidasan AK, Anto RJ, Pillai JJ, Kumar GS

International Journal of Nanomedicine 2012, 7:4077-4088

Published Date: 27 July 2012

Detemir as a once-daily basal insulin in type 2 diabetes

Nelson SE

Clinical Pharmacology: Advances and Applications 2011, 3:27-37

Published Date: 18 August 2011

Particle size reduction to the nanometer range: a promising approach to improve buccal absorption of poorly water-soluble drugs

Rao S, Song Y, Peddie F, Evans AM

International Journal of Nanomedicine 2011, 6:1245-1251

Published Date: 20 June 2011

Crystallization after intravitreal ganciclovir injection

Pitipol Choopong, Nattaporn Tesavibul, Nattawut Rodanant

Clinical Ophthalmology 2010, 4:709-711

Published Date: 14 July 2010